Genetic prediction of the metabolic syndrome

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 2, Issue 4, 2008, Pages 245-252

  Lyssenko, V ^a   Sjogren M ^a   Almgren, P ^a   Anevski, D ^a,b   Orho Melander, M ^a   Isomaa, B ^b   Tuomi, T ^c,d   Taskinen, M R ^c   Groop, L ^a  

^a LUND UNIVERSITY   (Sweden)

^b FRAUNHOFER CHALMERS CENTRE   (Sweden)

^c FOLKHÄLSAN RESEARCH CENTER   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Genetics; Metabolic syndrome; Prediction

Indexed keywords

ADIPONECTIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FOLLOW UP; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 55549110765     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2008.07.002     Document Type: Article

References (45)

1. Bosy-Westphal A., Onur S., Geisler C., Wolf A., Korth O., Pfeuffer M., et al. Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. Int J Obes Lond 31 (2007) 784-790
2. Groop L., Forsblom C., Lehtovirta M., Tuomi T., Karanko S., Nissen M., et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 45 (1996) 1585-1593
3. Freeman M.S., Mansfield M.W., Barrett J.H., and Grant P.J. Heritability of features of the insulin resistance syndrome in a community-based study of healthy families. Diabet Med 19 (2002) 994-999
4. Lin H.F., Boden-Albala B., Juo S.H., Park N., Rundek T., and Sacco R.L. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. Diabetologia 48 (2005) 2006-2012
5. Poulsen P., Vaag A., Kyvik K., and Beck-Nielsen H. Genetic versus environmental aetiology of the metabolic syndrome among male and female twins. Diabetologia 44 (2001) 537-543
6. Hong Y., Rice T., Gagnon J., Despres J.P., Nadeau A., Perusse L., et al. Familial clustering of insulin and abdominal visceral fat: the HERITAGE Family Study. J Clin Endocrinol Metab 83 (1998) 4239-4245
7. Rice T., Despres J.P., Daw E.W., Gagnon J., Borecki I.B., Perusse L., et al. Familial resemblance for abdominal visceral fat: the HERITAGE family study. Int J Obes Relat Metab Disord 21 (1997) 1024-1031
8. Rice T., Nadeau A., Perusse L., Bouchard C., and Rao D.C. Familial correlations in the Quebec family study: cross-trait familial resemblance for body fat with plasma glucose and insulin. Diabetologia 39 (1996) 1357-1364
9. Bouchard C. Genetics of body fat content. In: Angel H., Andersson H., Bouchard C., Lau D., Leiter L., and Mendelson R. (Eds). Progress in obesity research vol. 7 (1996), London, John Libbey 33-41
10. Carey D.G., Nguyen T.V., Campbell L.V., Chisholm D.J., and Kelly P. Genetic influences on central abdominal fat: a twin study. Int J Obes Relat Metab Disord 20 (1996) 722-726
11. Samaras K., Spector T.D., Nguyen T.V., Baan K., Campbell L.V., and Kelly P.J. Independent genetic factors determine the amount and distribution of fat in women after the menopause. J Clin Endocrinol Metab 82 (1997) 781-785
12. Tripathy D., Lindholm E., Isomaa B., Saloranta C., Tuomi T., and Groop L. Familiality of metabolic abnormalities is dependent on age at onset and phenotype of the type 2 diabetic proband. Am J Physiol Endocrinol Metab 285 (2003) E1297-1303
13. Lehtovirta M., Kaprio J., Forsblom C., Eriksson J., Tuomilehto J., and Groop L. Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins. Diabetologia 43 (2000) 285-293
14. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34 (2003) 267-273
15. Patti M.E., Butte A.J., Crunkhorn S., Cusi K., Berria R., Kashyap S., et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100 (2003) 8466-8471
16. Lyssenko V., Almgren P., Anevski D., Orho-Melander M., Sjogren M., Saloranta C., et al. Genetic prediction of future type 2 diabetes. PLoS Med 2 (2005) e345
17. World Health Organisation. Definition, diagnosis, and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus (1999), World Health Organisation, Geneva
18. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
19. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
20. Lyssenko V.A.P., Anevski D., Perfekt R., Lahti K., Nissén M., Isomaa B., Forsen B., Homström N., Saloranta C., Taskinen M.-R., Groop L., and Tuomi T. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 54 (2005) 166-174
21. Klein J.P., and Moeschberger M.L. Survival analysis: techniques for censored and truncated data (2003), Springer
22. Levy J.C., Matthews D.R., and Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21 (1998) 2191-2192
23. Altshuler D., Hirschhorn J.N., Klannemark M., Klannemark M., Lindgren C.M., Vohl M.C., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26 (2000) 76-80
24. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 42 (1999) 1033-1049
25. Douglas J.A., Erdos M.R., Watanabe R.M., Braun A., Johnston C.L., Oeth P., et al. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes 50 (2001) 886-890
26. Ek J., Andersen G., Urhammer S.A., Hansen L., Carstensen B., Borch-Johnsen K., et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44 (2001) 1170-1176
27. Ghoussaini M., Meyre D., Lobbens S., Charpentier G., Clement K., Charles M.A., et al. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet 6 (2005) 11
28. Hara K., Okada T., Tobe K., Yasuda K., Mori Y., Kadowaki H., et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271 (2000) 212-216
29. Vaccaro O., Mancini F.P., Ruffa G., Sabatino L., Colantuoni V., and Riccardi G. Pro12Ala mutation in the peroxisome proliferator-activated receptor gamma2 (PPARgamma2) and severe obesity: a case-control study. Int J Obes Relat Metab Disord 24 (2000) 1195-1199
30. Yilmaz M., Ergun M.A., Karakoc A., Yurtcu E., Yetkin I., Ayvaz G., et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome. Gynecol Endocrinol 21 (2005) 206-210
31. Beamer B.A., Yen C.J., Andersen R.E., Muller D., Elahi D., Cheskin L.J., et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 47 (1998) 1806-1808
32. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20 (1998) 284-287
33. Ek J., Urhammer S.A., Sorensen T.I., Andersen T., Auwerx J., and Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 42 (1999) 892-895
34. Hahn S., Fingerhut A., Khomtsiv U., Khomtsiv L., Tan S., Quadbeck B., et al. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62 (2005) 573-579
35. Yilmaz M., Ergun M.A., Karakoc A., Yurtcu E., Cakir N., and Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 22 (2006) 336-342
36. Tan G.D., Neville M.J., Liverani E., Humphreys S.M., Currie J.M., Dennis L., et al. The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia 49 (2006) 158-168
37. Memisoglu A., Hu F.B., Hankinson S.E., Manson J.E., De Vivo I., Willett W.C., et al. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 12 (2003) 2923-2929
38. Ylonen S.K., Salminen I., Lyssenko V., Virtanen S.M., Groop L., Aro A., et al. The Pro12Ala polymorphism of the PPAR-gamma2 gene affects associations of fish intake and marine n-3 fatty acids with glucose metabolism. Eur J Clin Nutr (2007)
39. Groop L.C., Bonadonna R.C., Shank M., Petrides A.S., and DeFronzo R.A. Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man. J Clin Invest 87 (1991) 83-89
40. Mason D.A., Moore J.D., Green S.A., and Liggett S.B. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274 (1999) 12670-12674
41. Ardilouze J.L., Fielding B.A., Currie J.M., Frayn K.N., and Karpe F. Nitric oxide and beta-adrenergic stimulation are major regulators of preprandial and postprandial subcutaneous adipose tissue blood flow in humans. Circulation 109 (2004) 47-52
42. Samra J.S., Simpson E.J., Clark M.L., Forster C.D., Humphreys S.M., Macdonald I.A., et al. Effects of epinephrine infusion on adipose tissue: interactions between blood flow and lipid metabolism. Am J Physiol 271 (1996) E834-839
43. Lima J.J., Feng H., Duckworth L., Wang J., Sylvester J.E., Kissoon N., et al. Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metab: Clin Exp 56 (2007) 757-765
44. Dessy C., Moniotte S., Ghisdal P., Havaux X., Noirhomme P., and Balligand J.L. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 110 (2004) 948-954
45. Dessy C., Saliez J., Ghisdal P., Daneau G., Lobysheva I.I., Frerart F., et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 112 (2005) 1198-1205